The 7th Advances in Circulating Tumor Cells (ACTC 2025) conference in Thessaloniki brought together international leaders in liquid biopsy research, from basic biology to clinical translation. Frontier’s own Dr. Lee and Dr. Burow were there to evaluate the global state of the field and position the qCTC system within ongoing conversations about the future of circulating tumour cell (CTC) technologies.
Dr Lee commented; “It’s really important for us to talk to key opinion leaders, compare our qCTC with others and gather the latest intelligence on validation pathways and clinical adoption challenges. Just sharing perspectives at plenary and poster sessions has meant we’re able to assess how our approach – balancing technical precision with clinical usability – —compares to emerging enrichment-free and multi-omic competitors. These insights are critical for refining qCTC development and ensuring it meets both scientific rigour and clinical relevance.”
Frontier’s qCTC System in the Context of ACTC
A central theme at ACTC 2025 has been the urgent need for quantitative, reproducible, and clinically actionable CTC analysis. Presentations have highlighted how enrichment-free platforms, high-volume detection, and multi-omic profiling are reshaping expectations for liquid biopsy. Against this backdrop, the qCTC system’s vision—delivering reliable CTC enumeration coupled with molecular depth from a single blood draw—is strongly aligned with where the field is heading.
The emphasis on minimal residual disease detection, therapy monitoring, and integration of CTC and ctDNA further validated Frontier’s strategy. While Frontier did not present at this meeting, the discourse confirmed that the qCTC platform’s focus on quantification and translational applicability directly addresses gaps acknowledged by the community.
From Frontier’s perspective, the ACTC 2025 meeting reinforced several points:
- Quantification matters: The field recognises that reliable enumeration remains a cornerstone for CTC utility in precision oncology.
- Integration is the future: Combining CTC analysis with ctDNA and other molecular readouts will define the next generation of liquid biopsy.
- Standardisation and validation are essential: For regulatory and clinical uptake, reproducibility across centers and harmonised methodologies will be mandatory.
- Frontier is well positioned: The qCTC system already anticipates these needs, aiming to provide a platform that bridges technical innovation with direct clinical application.